Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penile Allotransplantation for Genital Trauma
NCT03240822Phase 1Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2017
- Primary completion
- Dec 2022
01
Overview
Phase 1, open-label trial of alemtuzumab, sponsored by Wake Forest University Health Sciences. Primary endpoint: Need for Immunosuppressive drug therapy at 6 months. Planned start Jan 2017; status: withdrawn.
02
Drugs
alemtuzumab
Beyond the preview
Go deeper on NCT03240822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240822.